June 18, 2025 16:30 ET | Source: Cellectar Biosciences, Inc. FLORHAM PARK, N.J., June 18, 2025 (GLOBE NEWSWIRE) -- Cellectar…
COPENHAGEN, Denmark, June 18, 2025 /PRNewswire/ -- Droplet IV today announced the successful completion of a $2 million funding round…
CAESAREA, Israel, June 17, 2025 /PRNewswire/ -- A newly published, peer-reviewed study in Nature Scientific Reports, part of the prestigious Nature…
BOCA RATON, Fla.--(BUSINESS WIRE)--#AndrewQueen--Integrated Dermatology, the country’s largest independent dermatology provider, proudly announces the addition of Shayan Cheraghlou, MD, FAAD,…
XOANACYL is an oral therapy designed to address critical challenges in CKD, including Iron deficiency and hyperphosphatemia Averoa submitted XOANACYL…
Results from Phase IIb PADOVA and longer term follow-up data suggest clinical benefit on top of symptomatic treatment in early-stage…
ROCKVILLE, Md. and SUZHOU, China, June 15, 2025 (GLOBE NEWSWIRE) -- Ascentage Pharma (NASDAQ: AAPG; HKEX: 6855), a global biopharmaceutical…
After a thorough clinical review, the benefit-risk for the use of Elevidys in non-ambulatory patients with Duchenne has been re-assessed,…
June 14, 2025 10:48 ET | Source: Celldex Therapeutics, Inc. 77% of patients (150 mg Q4W) treated with barzolvolimab who…
Data demonstrates the potential for INCA033989 to modify disease by directly inhibiting and eliminating oncogenic mutCALR cells, while sparing healthy…